Market Trends Acelyrin jumps 11% on acquisition offer from Concentra Biosciences (SLRN:NASDAQ)By admin8996erT0allFebruary 21, 2025 Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash…
